Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Abstract: Described herein are glue degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment or prevention of conditions, diseases, and disorders mediated by various target proteins.

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: An elevated-beam cow stall assembly has a plurality of tubular cow stall dividers supported on a single horizontal beam. This provides room for the cow to lunge slightly to assist her in lying down or getting up. In an embodiment, stanchions or brackets are formed of vertical channel members affixed onto the beam. The tubular stall dividers each have an upper and a lower horizontal rail, the ends of which are mounted into the upper and lower ends of the channel member. Short upper and lower channel portions are fastened to the main vertical channel members, web-to-web, and the tubular stall dividers from a facing row of stalls are mounted on these. The brackets or stanchions may be mounted to the beam using square U-bolts, or by other techniques such as welding.

Abstract: Process for the preparation of a copolymer of maleic anhydride and an alkyl vinyl ether, comprising the steps of supplying maleic anhydride and the alkyl vinyl ether and an initiator, together forming a feed flow, through an inlet to a reactor wherein maleic anhydride and the alkyl vinyl ether react to a copolymer of maleic anhydride an alkyl vinyl ether thereby forming a reaction mixture with the maleic anhydride, the alkyl vinyl ether and the initiator characterized in that the process is a continuous process and the reactor is a loop reactor wherein the reaction mixture is internally circulated, whereby this reaction mixture arrives at the inlet before the maleic anhydride and alkyl vinyl ether have completely reacted while a remainder of initiator is still present. The invention further relates to copolymer of maleic anhydride and alkyl vinyl ether, including hydrolyzed or alcoholized copolymers, characterized in that a molecular weight distribution, expressed as Mw/Mn, is less than 2.

Abstract: An elevated-beam cow stall assembly employs angle brackets each installed on a respective vertical post. Support stanchions formed of a vertical rail, with upper and receiver members affixed at upper and lower ends of the rail, are attached to the back plates of the angle brackets, and the back plates also support the horizontal support beam. Tubular stall dividers each have an upper and a lower horizontal rail, the ends of which are mounted into the receivers of the stanchions. Additional stanchions may be affixed, i.e., with U-bolts, at intermediate locations along the horizontal beam, and these stanchions also support associated stall dividers. Neck rails may be attached to the upper rails of the dividers, and brisket rails or brisket pipes may be supported on the lower rails of the dividers. This construction permits an unobstructed space below the horizontal beam to give the cow some freedom of movement for lying down and rising.